Elranatamab
Written By Dr. Sakshi Jain
Reviewed By Dr. Rajeev SharmaLast updated 28 May 2026 | 12:16 PM (UTC)
Elranatamab Uses
Elranatamab is used in the treatment of multiple myeloma.
How Elranatamab works
Elranatamab is an antibody medicine that attaches to multiple myeloma cells carrying a marker called BCMA (B-cell maturation antigen). It helps the body’s immune system recognize and attack these cancer cells by bringing immune cells closer to them. This helps kill myeloma cells and slows the growth of the cancer.
Common side effects of Elranatamab
Cytokine release syndrome, Fatigue, Injection site reactions (pain, swelling, redness), Diarrhea, Upper respiratory tract infection, Musculoskeletal (bone, muscle or joint) pain, Pneumonia, Decreased appetite, Rash, Cough, Nausea, Fever, Decreased white blood cell count (lymphocytes), Decreased white blood cell count (neutrophils), Decreased hemoglobin, Decreased blood cells (red cells, white cells, and platelets)
Want to Know More
Read Our Editorial PolicyMedicine brands for Elranatamab
Expert advice for Elranatamab
- Inform your doctor immediately if you develop fever, chills, confusion, breathing difficulty, severe weakness, or changes in alertness after treatment.
- Maintain infection precautions, such as proper hand hygiene and avoiding close contact with people who have active infections, as treatment may weaken immune defenses.
- Stay well-hydrated and maintain balanced nutrition during treatment to help support recovery and overall health.
- Do not drive, operate heavy machinery, or perform activities requiring full alertness if you experience dizziness, confusion, or neurologic symptoms after receiving Elranatamab.
- Patients should inform their doctor about all medicines they are taking, including prescription medicines, supplements, and herbal products, to help avoid treatment-related complications.
Frequently asked questions for Elranatamab
Step-up dosing refers to receiving lower initial doses before moving to full treatment doses under close medical supervision. It is used to reduce the risk of cytokine release syndrome (CRS). It is a serious immune reaction that can occur during treatment.
CRS is an immune-related reaction that may occur when the immune system becomes highly activated during treatment. Symptoms may include fever, chills, low blood pressure, breathing difficulty, headache, or rapid heartbeat. Early monitoring is important because CRS can become serious in some patients.
Yes, it may cause neurologic toxicity, including confusion, dizziness, headache, difficulty speaking, sleepiness, or changes in alertness. Patients are monitored carefully for these symptoms during treatment.
The first few doses carry a higher risk of CRS and neurologic side effects. Because of these factors, hospitalization and close observation may be required after initial step-up doses to ensure patient safety.
Yes, it can weaken immune defenses and increase the risk of serious infections, including pneumonia and sepsis. Patients should immediately report symptoms such as fever, cough, sore throat, or breathing difficulty.
Yes. Regular monitoring of blood counts, liver function, and signs of infection is important during treatment to help identify side effects early and guide treatment decisions.